Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Ovarian Stimulation for IVF and Risk of Primary Breast Cancer in BRCA1/2 Mutation Carriers
- Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- ASCO 2018: New Evidence and Implications for Integrating NEPA for CINV
- ASCO 2018: Potential Role for PARP Inhibitor and PD-L1 Inhibitor Combination in Metastatic Triple Negative Breast Cancer
- ASCO 2018: Abstract Recommendations From Dr. Lee Schwartzberg
- Circulating Tumor Cell Status Predicts Radiotherapy Benefit in Early Breast Cancer
- Metastatic Breast Cancer: Later Lines of Therapy
- Metastatic Breast Cancer: Triple Negative
- Everolimus Plus Endocrine Therapy for Postmenopausal Women With ER+-Positive, HER2– Advanced Breast Cancer